207 related articles for article (PubMed ID: 21478921)
1. Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike.
Danylesko I; Shimoni A; Nagler A
Bone Marrow Transplant; 2012 Jan; 47(1):5-14. PubMed ID: 21478921
[TBL] [Abstract][Full Text] [Related]
2. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
3. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A
Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
[TBL] [Abstract][Full Text] [Related]
4. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
5. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
[TBL] [Abstract][Full Text] [Related]
6. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
[TBL] [Abstract][Full Text] [Related]
7. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
[TBL] [Abstract][Full Text] [Related]
9. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.
Holowiecki J; Giebel S; Wojnar J; Krawczyk-Kulis M; Markiewicz M; Holowiecka-Goral A; Freund M; Casper J
Br J Haematol; 2008 Jun; 142(2):284-92. PubMed ID: 18492101
[TBL] [Abstract][Full Text] [Related]
10. Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities.
Greystoke B; Bonanomi S; Carr TF; Gharib M; Khalid T; Coussons M; Jagani M; Naik P; Rao K; Goulden N; Amrolia P; Wynn RF; Veys PA
Br J Haematol; 2008 Jun; 142(2):257-62. PubMed ID: 18492115
[TBL] [Abstract][Full Text] [Related]
11. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma.
Schmidt-Hieber M; Blau IW; Trenschel R; Andreesen R; Stuhler G; Einsele H; Kanz L; Keilholz U; Marinets O; Beelen DW; Fauser AA; Volin L; Ruutu T; Uharek L; Fietz T; Knauf W; Hopfenmüller W; Thiel E; Freund M; Casper J
Bone Marrow Transplant; 2007 Apr; 39(7):389-96. PubMed ID: 17310135
[TBL] [Abstract][Full Text] [Related]
12. Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity.
Shimoni A; Shem-Tov N; Volchek Y; Danylesko I; Yerushalmi R; Nagler A
Bone Marrow Transplant; 2012 Oct; 47(10):1274-82. PubMed ID: 22327135
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes.
Shimoni A; Hardan I; Shem-Tov N; Rand A; Yerushalmi R; Nagler A
Leuk Lymphoma; 2007 Dec; 48(12):2352-9. PubMed ID: 18067010
[TBL] [Abstract][Full Text] [Related]
14. European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
Boztug H; Sykora KW; Slatter M; Zecca M; Veys P; Lankester A; Cant A; Skinner R; Wachowiak J; Glogova E; Pötschger U; Peters C
Pediatr Blood Cancer; 2016 Jan; 63(1):139-48. PubMed ID: 26398915
[TBL] [Abstract][Full Text] [Related]
15. Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.
Chemnitz JM; von Lilienfeld-Toal M; Holtick U; Theurich S; Shimabukuro-Vornhagen A; Krause A; Brossart P; Hallek M; Scheid C
Ann Hematol; 2012 Jan; 91(1):47-55. PubMed ID: 21584670
[TBL] [Abstract][Full Text] [Related]
16. Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation.
Casper J; Knauf W; Blau I; Ruutu T; Volin L; Wandt H; Schafer-Eckart K; Holowiecki J; Giebel S; Aschan J; Zander A; Kroger N; Doelken G; Freund M
Ann Hematol; 2004; 83 Suppl 1():S70-1. PubMed ID: 15124679
[TBL] [Abstract][Full Text] [Related]
17. [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
Casper J; Wilhelm S; Steiner B; Wolff D; Grobe N; Hähling D; Hartung G; Hilgendorf I; Lück A; Junghanss C; Kahl C; Baumgart J; Pichlmeier U; Freund M
Dtsch Med Wochenschr; 2005 Sep; 130(38):2125-9. PubMed ID: 16172951
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
19. Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome.
Hilgendorf I; Wolff D; Gromke T; Trenschel R; Elmaagacli AH; Pichlmeier U; Junghanss C; Freund M; Beelen DW; Casper J
Bone Marrow Transplant; 2011 Apr; 46(4):502-9. PubMed ID: 20581886
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Quigley J; Chen YH; Mahmud N; Hurter E; Beri R; Rondelli D
Bone Marrow Transplant; 2008 Jun; 41(11):935-40. PubMed ID: 18264144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]